- Home
- HPK vs SNY Comparison
HPK vs SNY Comparison
Compare HPK & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPK
- SNY
- Stock Information
- Founded
- HPK 2019
- SNY 1994
- Country
- HPK United States
- SNY France
- Employees
- HPK N/A
- SNY N/A
- Industry
- HPK Oil & Gas Production
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- HPK Energy
- SNY Health Care
- Exchange
- HPK Nasdaq
- SNY Nasdaq
- Market Cap
- HPK 1.1B
- SNY 113.4B
- IPO Year
- HPK N/A
- SNY N/A
- Fundamental
- Price
- HPK $7.13
- SNY $47.03
- Analyst Decision
- HPK Sell
- SNY Buy
- Analyst Count
- HPK 2
- SNY 4
- Target Price
- HPK $11.50
- SNY $61.50
- AVG Volume (30 Days)
- HPK 396.3K
- SNY 2.8M
- Earning Date
- HPK 11-03-2025
- SNY 10-24-2025
- Dividend Yield
- HPK 2.24%
- SNY 3.40%
- EPS Growth
- HPK N/A
- SNY 118.56
- EPS
- HPK 0.86
- SNY 8.65
- Revenue
- HPK $964,232,000.00
- SNY $53,714,621,258.00
- Revenue This Year
- HPK N/A
- SNY $2.01
- Revenue Next Year
- HPK N/A
- SNY $6.82
- P/E Ratio
- HPK $8.29
- SNY $10.74
- Revenue Growth
- HPK N/A
- SNY 15.65
- 52 Week Low
- HPK $7.00
- SNY $44.73
- 52 Week High
- HPK $16.56
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- HPK 37.63
- SNY 42.55
- Support Level
- HPK $7.41
- SNY $46.79
- Resistance Level
- HPK $7.75
- SNY $47.69
- Average True Range (ATR)
- HPK 0.33
- SNY 0.71
- MACD
- HPK 0.02
- SNY -0.27
- Stochastic Oscillator
- HPK 6.02
- SNY 32.62
About HPK HighPeak Energy Inc.
HighPeak Energy Inc is an independent crude oil and natural gas company focused on the development of unconventional oil and natural gas reserves in Howard County of the Midland Basin. The company operates in a single segment, which is crude oil and natural gas development, exploration, and production in the U.S.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.